Supartz FX Injection Launched for Knee Osteoarthritis Pain
Bioventus announced the launch of Supartz FX (hyaluronic acid) for the management of knee osteoarthritis pain in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (eg, acetaminophen). Supartz FX has an expanded safety label that allows for repeat injection cycles.
Supartz FX, a viscosupplement, works by helping to restore the body's natural hyaluronic acid production that may help preserve lubricity of bearing joint surfaces such as the knee. Products containing hyaluronic acid may also delay the need for total knee replacement. It is a non-surgical, non-pharmacologic therapy intended for knee osteoarthritis.
In a multicenter, prospective, randomized, double-blind, placebo-controlled trial (n=240), Supartz FX significantly relieved osteoarthritis pain that lasted at least 18 weeks, in patients with knee osteoarthritis. In a retrospective analysis of healthcare claims database in about 79 million patients, treatment with hyaluronic acid, including Supartz FX, delayed the time total knee replacement by up to 3.6 years.
Supartz FX is available as a sterile, non-pyrogenic solution in 2.5mL pre-filled syringes.
For more information call (800) 396-4325 or visit SupartzFX.com.